# A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

> **NCT02302339** · PHASE2 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 132 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** glembatumumab vedotin
- **DRUG:** glembatumumab vedotin and varlilumab
- **DRUG:** glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- **DRUG:** glembatumumab vedotin and CDX-301

## Key facts

- **NCT ID:** NCT02302339
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2018-06-14
- **Final completion:** 2018-10-03
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** Development of glembatumumab vedotin was discontinued
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02302339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02302339, "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT02302339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*